array(40) {
  [0]=>
  string(4) "8941"
  ["article_id"]=>
  string(4) "8941"
  [1]=>
  string(50) "Renishaw joins nationwide effort to fight Covid-19"
  ["article_title"]=>
  string(50) "Renishaw joins nationwide effort to fight Covid-19"
  [2]=>
  string(150) "Renishaw has started mass-producing critical components for medical ventilators, as part of a nationwide effort to support the NHS in the fight agains"
  ["short_description"]=>
  string(150) "Renishaw has started mass-producing critical components for medical ventilators, as part of a nationwide effort to support the NHS in the fight agains"
  [3]=>
  string(161) "Renishaw has started mass-producing critical components for medical ventilators, as part of a nationwide effort to support the NHS in the fight against Covid-19."
  ["description"]=>
  string(161) "Renishaw has started mass-producing critical components for medical ventilators, as part of a nationwide effort to support the NHS in the fight against Covid-19."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "41"
  ["rss_id"]=>
  string(2) "41"
  [14]=>
  string(92) "https://www.medicalplasticsnews.com/news/renishaw-joins-nationwide-effort-to-fight-covid-19/"
  ["blog_url"]=>
  string(92) "https://www.medicalplasticsnews.com/news/renishaw-joins-nationwide-effort-to-fight-covid-19/"
  [15]=>
  string(19) "2020-04-08 18:27:14"
  ["add_date"]=>
  string(19) "2020-04-08 18:27:14"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-04-12 16:42:21"
  ["create_at"]=>
  string(19) "2020-04-12 16:42:21"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "8942"
  ["article_id"]=>
  string(4) "8942"
  [1]=>
  string(46) "How to ensure sustainability within healthcare"
  ["article_title"]=>
  string(46) "How to ensure sustainability within healthcare"
  [2]=>
  string(154) "Deepak Prakash, senior director of global marketing at Avery Dennison Medical, describes the path to progress in healthcare industry sustainability."
  ["short_description"]=>
  string(154) "Deepak Prakash, senior director of global marketing at Avery Dennison Medical, describes the path to progress in healthcare industry sustainability."
  [3]=>
  string(154) "Deepak Prakash, senior director of global marketing at Avery Dennison Medical, describes the path to progress in healthcare industry sustainability."
  ["description"]=>
  string(154) "Deepak Prakash, senior director of global marketing at Avery Dennison Medical, describes the path to progress in healthcare industry sustainability."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "41"
  ["rss_id"]=>
  string(2) "41"
  [14]=>
  string(56) "https://www.medicalplasticsnews.com/news/chain-reaction/"
  ["blog_url"]=>
  string(56) "https://www.medicalplasticsnews.com/news/chain-reaction/"
  [15]=>
  string(19) "2020-04-08 18:15:22"
  ["add_date"]=>
  string(19) "2020-04-08 18:15:22"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-04-12 16:42:21"
  ["create_at"]=>
  string(19) "2020-04-12 16:42:21"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "8943"
  ["article_id"]=>
  string(4) "8943"
  [1]=>
  string(57) "Different dimensions: Addressing challenges with neonates"
  ["article_title"]=>
  string(57) "Different dimensions: Addressing challenges with neonates"
  [2]=>
  string(155) "Christelle Letourmy, principal international marketing manager – BU obstetrics neonatology enteral, from specialist single-use medical devices group"
  ["short_description"]=>
  string(155) "Christelle Letourmy, principal international marketing manager – BU obstetrics neonatology enteral, from specialist single-use medical devices group"
  [3]=>
  string(239) "Christelle Letourmy, principal international marketing manager – BU obstetrics neonatology enteral, from specialist single-use medical devices group Vygon, explains why neonatology requires specialised staff, procedures and devices."
  ["description"]=>
  string(239) "Christelle Letourmy, principal international marketing manager – BU obstetrics neonatology enteral, from specialist single-use medical devices group Vygon, explains why neonatology requires specialised staff, procedures and devices."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "41"
  ["rss_id"]=>
  string(2) "41"
  [14]=>
  string(98) "https://www.medicalplasticsnews.com/news/different-dimensions-addressing-challenges-with-neonates/"
  ["blog_url"]=>
  string(98) "https://www.medicalplasticsnews.com/news/different-dimensions-addressing-challenges-with-neonates/"
  [15]=>
  string(19) "2020-04-08 18:00:47"
  ["add_date"]=>
  string(19) "2020-04-08 18:00:47"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-04-12 16:42:21"
  ["create_at"]=>
  string(19) "2020-04-12 16:42:21"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "8757"
  ["article_id"]=>
  string(4) "8757"
  [1]=>
  string(47) "Expanded EU approval for Takeda's Alunbrig "
  ["article_title"]=>
  string(47) "Expanded EU approval for Takeda's Alunbrig "
  [2]=>
  string(132) "The expanded indication provides the around 10,000 people living with ALK+ NSCLC in Europe an additional first-line treatment option"
  ["short_description"]=>
  string(132) "The expanded indication provides the around 10,000 people living with ALK+ NSCLC in Europe an additional first-line treatment option"
  [3]=>
  string(132) "The expanded indication provides the around 10,000 people living with ALK+ NSCLC in Europe an additional first-line treatment option"
  ["description"]=>
  string(132) "The expanded indication provides the around 10,000 people living with ALK+ NSCLC in Europe an additional first-line treatment option"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(1) "4"
  ["rss_id"]=>
  string(1) "4"
  [14]=>
  string(81) "http://www.pharmatimes.com/news/expanded_eu_approval_for_takedas_alunbrig_1337936"
  ["blog_url"]=>
  string(81) "http://www.pharmatimes.com/news/expanded_eu_approval_for_takedas_alunbrig_1337936"
  [15]=>
  string(19) "2020-04-08 16:24:54"
  ["add_date"]=>
  string(19) "2020-04-08 16:24:54"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-04-12 16:36:37"
  ["create_at"]=>
  string(19) "2020-04-12 16:36:37"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "8936"
  ["article_id"]=>
  string(4) "8936"
  [1]=>
  string(42) "Rushing Supplies to the COVID-19 Forefront"
  ["article_title"]=>
  string(42) "Rushing Supplies to the COVID-19 Forefront"
  [2]=>
  string(153) "&#nlHealthcare providers responding to the COVID-19 crisis need significant amounts of diagnostic testing supplies, protective personal equipment, respir"
  ["short_description"]=>
  string(153) "&#nlHealthcare providers responding to the COVID-19 crisis need significant amounts of diagnostic testing supplies, protective personal equipment, respir"
  [3]=>
  string(5477) "&#nl
Healthcare providers responding to the COVID-19 crisis need significant amounts of diagnostic testing supplies, protective personal equipment, respiratory treatment equipment and supplies, and a host of other items, according to an April 2020 report from the U.S. Department of Health and Human Services. And as treatment centers have emerged in nontraditional locations to back up hospitals, these supplies are needed in some unique areas.
&#nl
The Global Healthcare Exchange (GHX) has set up the COVID-19 Information Center to help both healthcare organizations and manufacturers of medical supplies manage any shortages and navigate a a shifting supply chain. The group has also developed a Critical Supply Reference List to help providers identify supplies and potential alternatives as well as offer greater visibility into the fluctuating demand for products, GHX explained in a news release.
&#nl
“The COVID-19 pandemic places intense pressure on manufacturers to get critical products into market faster,” Denise Odenkirk, vice president, supplier sales, GHX, told MD+DI. “GHX is leveraging several solutions and has created a few resources to help manufacturers.”
&#nl
MD+DI asked Odenkirk how GHX can help these manufacturers get their products into the supply chain faster.
&#nl
“As providers rapidly create overflow care locations—hotels, conference centers, outdoor areas—GHX has enabled a team to configure and enable these new locations and ensure supplies reach them,” she explained. “Manufacturers can leverage standard GHX tools to enable their order-to-cash processes with these overflow locations in a fast, seamless manner.”
&#nl
GHX is “also bringing manufacturers onto the GHX digital trading network, allowing for fast ramp up,” Odenkirk said. “For manufacturers not currently on the Exchange, GHX can quickly set up manufacturers to use Web Direct so that they can receive orders from providers that are integrated with the GHX Exchange. This helps providers enormously because ordering is automated, and manufacturers can quickly confirm orders through the portal.”
&#nl
Manufacturers can also sell through such medical-surgical distributors as “Cardinal Health, Medline, Owens and Minor, Henry Schein, Thermo Fisher, VWR, McKesson, Amerisource Bergen and Concordance, etc., Odenkirk said. “Each of these distributors are on the GHX Exchange and can accept automated orders for approximately 85% of the hospitals in North America,” she said.
&#nl
Manufacturers may need to develop strategies for managing unique issues.
&#nl
For instance, in times of medical supply shortages, manufacturers are faced with the need to ration when fulfilling orders,” Odenkirk said. “This is particularly critical right now as the national stockpile is nearly depleted. When rationing, it’s critical for manufacturers to clearly communicate to providers if they need orders to be sent with specific quantity limits.”
&#nl
Contract pricing may be another issue, which Odenkirk calls “one of the biggest complexities in med supplies.” She said that “to expedite supply ordering and simplify the full order-to-cash process, it’s best to keep pricing structures simple. One way to accomplish this is to establish one price for all providers regardless of volumes.”
&#nl
Finally, manufacturers will need to assure providers of their legitimacy. “The unfortunate reality is that with crisis comes the opportunity for fraud,” said Odenkirk. “Manufacturers will need to demonstrate that they have been properly vetted and meet the required criteria. The American Hospital Association (AHA) and The Association for Resource and Materials Management (AHRMM) [have] created a process to vet manufacturers on behalf of providers. It would be ideal for manufacturers who have supplies of critical medical products, especially PPE, to proactively reach out to these organizations to complete the vetting process.”
&#nl
Bruce Johnson, president and CEO, GHX, stated in the release that, “as the leading convener of providers and suppliers, GHX is in a unique position to help healthcare organizations keep pace with heightened demands during this critically imperative time. Our team mobilized to create a detailed resource center to answer the call for timely, accurate information, and actionable tools. We believe knowledge-sharing and open access to data will be key elements in managing through this crisis.”
"
  ["description"]=>
  string(5477) "&#nl
Healthcare providers responding to the COVID-19 crisis need significant amounts of diagnostic testing supplies, protective personal equipment, respiratory treatment equipment and supplies, and a host of other items, according to an April 2020 report from the U.S. Department of Health and Human Services. And as treatment centers have emerged in nontraditional locations to back up hospitals, these supplies are needed in some unique areas.
&#nl
The Global Healthcare Exchange (GHX) has set up the COVID-19 Information Center to help both healthcare organizations and manufacturers of medical supplies manage any shortages and navigate a a shifting supply chain. The group has also developed a Critical Supply Reference List to help providers identify supplies and potential alternatives as well as offer greater visibility into the fluctuating demand for products, GHX explained in a news release.
&#nl
“The COVID-19 pandemic places intense pressure on manufacturers to get critical products into market faster,” Denise Odenkirk, vice president, supplier sales, GHX, told MD+DI. “GHX is leveraging several solutions and has created a few resources to help manufacturers.”
&#nl
MD+DI asked Odenkirk how GHX can help these manufacturers get their products into the supply chain faster.
&#nl
“As providers rapidly create overflow care locations—hotels, conference centers, outdoor areas—GHX has enabled a team to configure and enable these new locations and ensure supplies reach them,” she explained. “Manufacturers can leverage standard GHX tools to enable their order-to-cash processes with these overflow locations in a fast, seamless manner.”
&#nl
GHX is “also bringing manufacturers onto the GHX digital trading network, allowing for fast ramp up,” Odenkirk said. “For manufacturers not currently on the Exchange, GHX can quickly set up manufacturers to use Web Direct so that they can receive orders from providers that are integrated with the GHX Exchange. This helps providers enormously because ordering is automated, and manufacturers can quickly confirm orders through the portal.”
&#nl
Manufacturers can also sell through such medical-surgical distributors as “Cardinal Health, Medline, Owens and Minor, Henry Schein, Thermo Fisher, VWR, McKesson, Amerisource Bergen and Concordance, etc., Odenkirk said. “Each of these distributors are on the GHX Exchange and can accept automated orders for approximately 85% of the hospitals in North America,” she said.
&#nl
Manufacturers may need to develop strategies for managing unique issues.
&#nl
For instance, in times of medical supply shortages, manufacturers are faced with the need to ration when fulfilling orders,” Odenkirk said. “This is particularly critical right now as the national stockpile is nearly depleted. When rationing, it’s critical for manufacturers to clearly communicate to providers if they need orders to be sent with specific quantity limits.”
&#nl
Contract pricing may be another issue, which Odenkirk calls “one of the biggest complexities in med supplies.” She said that “to expedite supply ordering and simplify the full order-to-cash process, it’s best to keep pricing structures simple. One way to accomplish this is to establish one price for all providers regardless of volumes.”
&#nl
Finally, manufacturers will need to assure providers of their legitimacy. “The unfortunate reality is that with crisis comes the opportunity for fraud,” said Odenkirk. “Manufacturers will need to demonstrate that they have been properly vetted and meet the required criteria. The American Hospital Association (AHA) and The Association for Resource and Materials Management (AHRMM) [have] created a process to vet manufacturers on behalf of providers. It would be ideal for manufacturers who have supplies of critical medical products, especially PPE, to proactively reach out to these organizations to complete the vetting process.”
&#nl
Bruce Johnson, president and CEO, GHX, stated in the release that, “as the leading convener of providers and suppliers, GHX is in a unique position to help healthcare organizations keep pace with heightened demands during this critically imperative time. Our team mobilized to create a detailed resource center to answer the call for timely, accurate information, and actionable tools. We believe knowledge-sharing and open access to data will be key elements in managing through this crisis.”
"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "40"
  ["rss_id"]=>
  string(2) "40"
  [14]=>
  string(62) "https://www.mddionline.com/rushing-supplies-covid-19-forefront"
  ["blog_url"]=>
  string(62) "https://www.mddionline.com/rushing-supplies-covid-19-forefront"
  [15]=>
  string(19) "2020-04-08 15:14:55"
  ["add_date"]=>
  string(19) "2020-04-08 15:14:55"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-04-12 16:42:20"
  ["create_at"]=>
  string(19) "2020-04-12 16:42:20"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "8925"
  ["article_id"]=>
  string(4) "8925"
  [1]=>
  string(68) "Keros Therapeutics Raises $96M in Upsized IPO to Fuel Clinical Tests"
  ["article_title"]=>
  string(68) "Keros Therapeutics Raises $96M in Upsized IPO to Fuel Clinical Tests"
  [2]=>
  string(150) "The financial markets may remain volatile but Keros Therapeutics (NASDAQ: KROS) managed to raise more money in its public market debut than it had ini"
  ["short_description"]=>
  string(150) "The financial markets may remain volatile but Keros Therapeutics (NASDAQ: KROS) managed to raise more money in its public market debut than it had ini"
  [3]=>
  string(353) "The financial markets may remain volatile but Keros Therapeutics (NASDAQ: KROS) managed to raise more money in its public market debut than it had initially planned. Late Tuesday, the Lexington, MA-based company offered 6 million shares for $16 apiece, the high end of its projected price range. Keros had previously planned to offer 5 million […]"
  ["description"]=>
  string(353) "The financial markets may remain volatile but Keros Therapeutics (NASDAQ: KROS) managed to raise more money in its public market debut than it had initially planned. Late Tuesday, the Lexington, MA-based company offered 6 million shares for $16 apiece, the high end of its projected price range. Keros had previously planned to offer 5 million […]"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "36"
  ["rss_id"]=>
  string(2) "36"
  [14]=>
  string(106) "https://xconomy.com/boston/2020/04/08/keros-therapeutics-raises-96m-in-upsized-ipo-to-fuel-clinical-tests/"
  ["blog_url"]=>
  string(106) "https://xconomy.com/boston/2020/04/08/keros-therapeutics-raises-96m-in-upsized-ipo-to-fuel-clinical-tests/"
  [15]=>
  string(19) "2020-04-08 15:09:51"
  ["add_date"]=>
  string(19) "2020-04-08 15:09:51"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-04-12 16:42:12"
  ["create_at"]=>
  string(19) "2020-04-12 16:42:12"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "8926"
  ["article_id"]=>
  string(4) "8926"
  [1]=>
  string(71) "Inovio Begins Experimental COVID-19 Vaccine Tests in Healthy Volunteers"
  ["article_title"]=>
  string(71) "Inovio Begins Experimental COVID-19 Vaccine Tests in Healthy Volunteers"
  [2]=>
  string(155) "Inovio Pharmaceuticals, one of the biotechs developing a vaccine to prevent COVID-19, has received the FDA’s OK to start testing its candidate in he"
  ["short_description"]=>
  string(155) "Inovio Pharmaceuticals, one of the biotechs developing a vaccine to prevent COVID-19, has received the FDA’s OK to start testing its candidate in he"
  [3]=>
  string(366) "Inovio Pharmaceuticals, one of the biotechs developing a vaccine to prevent COVID-19, has received the FDA’s OK to start testing its candidate in healthy volunteers. The Plymouth Meeting, PA-based company, which also conducts research in San Diego, plans to enroll as many as 40 adults across two trial locations. Inovio (NASDAQ: INO) said Monday it […]"
  ["description"]=>
  string(366) "Inovio Pharmaceuticals, one of the biotechs developing a vaccine to prevent COVID-19, has received the FDA’s OK to start testing its candidate in healthy volunteers. The Plymouth Meeting, PA-based company, which also conducts research in San Diego, plans to enroll as many as 40 adults across two trial locations. Inovio (NASDAQ: INO) said Monday it […]"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "36"
  ["rss_id"]=>
  string(2) "36"
  [14]=>
  string(112) "https://xconomy.com/national/2020/04/08/inovio-begins-experimental-covid-19-vaccine-tests-in-healthy-volunteers/"
  ["blog_url"]=>
  string(112) "https://xconomy.com/national/2020/04/08/inovio-begins-experimental-covid-19-vaccine-tests-in-healthy-volunteers/"
  [15]=>
  string(19) "2020-04-08 13:03:51"
  ["add_date"]=>
  string(19) "2020-04-08 13:03:51"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-04-12 16:42:12"
  ["create_at"]=>
  string(19) "2020-04-12 16:42:12"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "8912"
  ["article_id"]=>
  string(4) "8912"
  [1]=>
  string(73) "Could vitamin D play a role in coronavirus resistance? Research thinks so"
  ["article_title"]=>
  string(73) "Could vitamin D play a role in coronavirus resistance? Research thinks so"
  [2]=>
  string(150) "Vitamin D supplements may aid in the resistance of respiratory infections such as the coronavirus or limit the severity of the illness in those infect"
  ["short_description"]=>
  string(150) "Vitamin D supplements may aid in the resistance of respiratory infections such as the coronavirus or limit the severity of the illness in those infect"
  [3]=>
  string(179) "Vitamin D supplements may aid in the resistance of respiratory infections such as the coronavirus or limit the severity of the illness in those infected, according to researchers."
  ["description"]=>
  string(179) "Vitamin D supplements may aid in the resistance of respiratory infections such as the coronavirus or limit the severity of the illness in those infected, according to researchers."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "35"
  ["rss_id"]=>
  string(2) "35"
  [14]=>
  string(157) "https://www.nutraingredients.com/Article/2020/04/08/Could-vitamin-D-play-a-role-in-coronavirus-resistance?utm_source=RSS_Feed&utm_medium=RSS&utm_campaign=RSS"
  ["blog_url"]=>
  string(157) "https://www.nutraingredients.com/Article/2020/04/08/Could-vitamin-D-play-a-role-in-coronavirus-resistance?utm_source=RSS_Feed&utm_medium=RSS&utm_campaign=RSS"
  [15]=>
  string(19) "2020-04-08 13:00:00"
  ["add_date"]=>
  string(19) "2020-04-08 13:00:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-04-12 16:42:12"
  ["create_at"]=>
  string(19) "2020-04-12 16:42:12"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "8828"
  ["article_id"]=>
  string(4) "8828"
  [1]=>
  string(46) "WHO Favors COVID-19 Intellectual Property Pool"
  ["article_title"]=>
  string(46) "WHO Favors COVID-19 Intellectual Property Pool"
  [2]=>
  string(158) "&#nl        The World Health Organization’s director-general has endorsed the voluntary sharing of patent rights and pooling of data to help develop CO"
  ["short_description"]=>
  string(158) "&#nl        The World Health Organization’s director-general has endorsed the voluntary sharing of patent rights and pooling of data to help develop CO"
  [3]=>
  string(181) "&#nl        The World Health Organization’s director-general has endorsed the voluntary sharing of patent rights and pooling of data to help develop COVID-19 drugs.&#nl      "
  ["description"]=>
  string(181) "&#nl        The World Health Organization’s director-general has endorsed the voluntary sharing of patent rights and pooling of data to help develop COVID-19 drugs.&#nl      "
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "16"
  ["rss_id"]=>
  string(2) "16"
  [14]=>
  string(86) "https://www.fdanews.com/articles/196569-who-favors-covid-19-intellectual-property-pool"
  ["blog_url"]=>
  string(86) "https://www.fdanews.com/articles/196569-who-favors-covid-19-intellectual-property-pool"
  [15]=>
  string(19) "2020-04-08 12:01:00"
  ["add_date"]=>
  string(19) "2020-04-08 12:01:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-04-12 16:36:46"
  ["create_at"]=>
  string(19) "2020-04-12 16:36:46"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "8829"
  ["article_id"]=>
  string(4) "8829"
  [1]=>
  string(59) "Ely Lilly Offers $35 Insulin Co-Pay in Response to COVID-19"
  ["article_title"]=>
  string(59) "Ely Lilly Offers $35 Insulin Co-Pay in Response to COVID-19"
  [2]=>
  string(153) "&#nl        Eli Lilly yesterday introduced a $35 monthly insulin co-pay for patients with or without commercial insurance to ensure they have access to t"
  ["short_description"]=>
  string(153) "&#nl        Eli Lilly yesterday introduced a $35 monthly insulin co-pay for patients with or without commercial insurance to ensure they have access to t"
  [3]=>
  string(207) "&#nl        Eli Lilly yesterday introduced a $35 monthly insulin co-pay for patients with or without commercial insurance to ensure they have access to the diabetes drug during the COVID-19 crisis.&#nl      "
  ["description"]=>
  string(207) "&#nl        Eli Lilly yesterday introduced a $35 monthly insulin co-pay for patients with or without commercial insurance to ensure they have access to the diabetes drug during the COVID-19 crisis.&#nl      "
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "16"
  ["rss_id"]=>
  string(2) "16"
  [14]=>
  string(98) "https://www.fdanews.com/articles/196568-ely-lilly-offers-35-insulin-co-pay-in-response-to-covid-19"
  ["blog_url"]=>
  string(98) "https://www.fdanews.com/articles/196568-ely-lilly-offers-35-insulin-co-pay-in-response-to-covid-19"
  [15]=>
  string(19) "2020-04-08 12:01:00"
  ["add_date"]=>
  string(19) "2020-04-08 12:01:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-04-12 16:36:46"
  ["create_at"]=>
  string(19) "2020-04-12 16:36:46"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "8792"
  ["article_id"]=>
  string(4) "8792"
  [1]=>
  string(158) "FDA Approves Braftovi (encorafenib) in Combination with Cetuximab for the Treatment of BRAFV600E-Mutant Metastatic Colorectal Cancer (CRC) After Prior Therapy"
  ["article_title"]=>
  string(158) "FDA Approves Braftovi (encorafenib) in Combination with Cetuximab for the Treatment of BRAFV600E-Mutant Metastatic Colorectal Cancer (CRC) After Prior Therapy"
  [2]=>
  string(150) "April 8, 2020 - Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved Braftovi® (encorafenib) in c"
  ["short_description"]=>
  string(150) "April 8, 2020 - Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved Braftovi® (encorafenib) in c"
  [3]=>
  string(246) "April 8, 2020 - Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved Braftovi® (encorafenib) in combination with cetuximab (marketed as ERBITUX®) for the treatment of adult patients with..."
  ["description"]=>
  string(246) "April 8, 2020 - Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved Braftovi® (encorafenib) in combination with cetuximab (marketed as ERBITUX®) for the treatment of adult patients with..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(1) "8"
  ["rss_id"]=>
  string(1) "8"
  [14]=>
  string(300) "https://www.drugs.com/newdrugs/fda-approves-braftovi-encorafenib-combination-cetuximab-brafv600e-mutant-metastatic-colorectal-5201.html?utm_source=ddc&utm_medium=rss&utm_campaign=FDA+Approves+Braftovi+%28encorafenib%29+in+Combination+with+Cetuximab+for+the+Treatment+of+BRAFV600E-Mutant+Metastatic+Co"
  ["blog_url"]=>
  string(300) "https://www.drugs.com/newdrugs/fda-approves-braftovi-encorafenib-combination-cetuximab-brafv600e-mutant-metastatic-colorectal-5201.html?utm_source=ddc&utm_medium=rss&utm_campaign=FDA+Approves+Braftovi+%28encorafenib%29+in+Combination+with+Cetuximab+for+the+Treatment+of+BRAFV600E-Mutant+Metastatic+Co"
  [15]=>
  string(19) "2020-04-08 11:04:59"
  ["add_date"]=>
  string(19) "2020-04-08 11:04:59"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-04-12 16:36:38"
  ["create_at"]=>
  string(19) "2020-04-12 16:36:38"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "8927"
  ["article_id"]=>
  string(4) "8927"
  [1]=>
  string(70) "Sage Restructuring Halves Staff, Turns Focus to Failed Depression Drug"
  ["article_title"]=>
  string(70) "Sage Restructuring Halves Staff, Turns Focus to Failed Depression Drug"
  [2]=>
  string(150) "Sage Therapeutics is cutting workers who sell its only commercialized drug in a corporate reorganization that it says allows it to focus on clinical-s"
  ["short_description"]=>
  string(150) "Sage Therapeutics is cutting workers who sell its only commercialized drug in a corporate reorganization that it says allows it to focus on clinical-s"
  [3]=>
  string(354) "Sage Therapeutics is cutting workers who sell its only commercialized drug in a corporate reorganization that it says allows it to focus on clinical-stage compounds, including a depression treatment that failed a pivotal test late last year. The corporate shakeup will eliminate the jobs of 340 employees, or about 53 percent of its staff, Sage […]"
  ["description"]=>
  string(354) "Sage Therapeutics is cutting workers who sell its only commercialized drug in a corporate reorganization that it says allows it to focus on clinical-stage compounds, including a depression treatment that failed a pivotal test late last year. The corporate shakeup will eliminate the jobs of 340 employees, or about 53 percent of its staff, Sage […]"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "36"
  ["rss_id"]=>
  string(2) "36"
  [14]=>
  string(108) "https://xconomy.com/boston/2020/04/07/sage-restructuring-halves-staff-turns-focus-to-failed-depression-drug/"
  ["blog_url"]=>
  string(108) "https://xconomy.com/boston/2020/04/07/sage-restructuring-halves-staff-turns-focus-to-failed-depression-drug/"
  [15]=>
  string(19) "2020-04-08 07:59:52"
  ["add_date"]=>
  string(19) "2020-04-08 07:59:52"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-04-12 16:42:12"
  ["create_at"]=>
  string(19) "2020-04-12 16:42:12"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}